An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)
Status:
Completed
Trial end date:
2018-06-12
Target enrollment:
Participant gender:
Summary
Evaluate safety and efficacy of intravenous (IV) iron isomaltoside/ferric derisomaltose
re-dosing, in subjects who were previously treated with iron isomaltoside/ferric
derisomaltose.